JP6994140B2 - 非ウイルス的遺伝子導入のための閉鎖型直鎖状二重鎖ｄｎａ - Google Patents

非ウイルス的遺伝子導入のための閉鎖型直鎖状二重鎖ｄｎａ Download PDF

Info

Publication number
JP6994140B2
JP6994140B2 JP2018546429A JP2018546429A JP6994140B2 JP 6994140 B2 JP6994140 B2 JP 6994140B2 JP 2018546429 A JP2018546429 A JP 2018546429A JP 2018546429 A JP2018546429 A JP 2018546429A JP 6994140 B2 JP6994140 B2 JP 6994140B2
Authority
JP
Japan
Prior art keywords
nucleic acid
sequence
cedna
protein
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018546429A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019506889A (ja
JP2019506889A5 (cg-RX-API-DMAC7.html
Inventor
コーチン，ロバート，エム．
チェッキーニ，シルヴァン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Voyager Therapeutics Inc
Original Assignee
Voyager Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Voyager Therapeutics Inc filed Critical Voyager Therapeutics Inc
Publication of JP2019506889A publication Critical patent/JP2019506889A/ja
Publication of JP2019506889A5 publication Critical patent/JP2019506889A5/ja
Priority to JP2021179896A priority Critical patent/JP7193096B2/ja
Application granted granted Critical
Publication of JP6994140B2 publication Critical patent/JP6994140B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
JP2018546429A 2016-03-03 2017-03-03 非ウイルス的遺伝子導入のための閉鎖型直鎖状二重鎖ｄｎａ Active JP6994140B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021179896A JP7193096B2 (ja) 2016-03-03 2021-11-03 非ウイルス的遺伝子導入のための閉鎖型直鎖状二重鎖ｄｎａ

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662303047P 2016-03-03 2016-03-03
US62/303,047 2016-03-03
US201662394720P 2016-09-14 2016-09-14
US62/394,720 2016-09-14
US201662406913P 2016-10-11 2016-10-11
US62/406,913 2016-10-11
PCT/US2017/020828 WO2017152149A1 (en) 2016-03-03 2017-03-03 Closed-ended linear duplex dna for non-viral gene transfer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021179896A Division JP7193096B2 (ja) 2016-03-03 2021-11-03 非ウイルス的遺伝子導入のための閉鎖型直鎖状二重鎖ｄｎａ

Publications (3)

Publication Number Publication Date
JP2019506889A JP2019506889A (ja) 2019-03-14
JP2019506889A5 JP2019506889A5 (cg-RX-API-DMAC7.html) 2020-04-09
JP6994140B2 true JP6994140B2 (ja) 2022-02-03

Family

ID=59743259

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018546429A Active JP6994140B2 (ja) 2016-03-03 2017-03-03 非ウイルス的遺伝子導入のための閉鎖型直鎖状二重鎖ｄｎａ
JP2021179896A Active JP7193096B2 (ja) 2016-03-03 2021-11-03 非ウイルス的遺伝子導入のための閉鎖型直鎖状二重鎖ｄｎａ
JP2022191114A Pending JP2023024489A (ja) 2016-03-03 2022-11-30 非ウイルス的遺伝子導入のための閉鎖型直鎖状二重鎖ｄｎａ

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021179896A Active JP7193096B2 (ja) 2016-03-03 2021-11-03 非ウイルス的遺伝子導入のための閉鎖型直鎖状二重鎖ｄｎａ
JP2022191114A Pending JP2023024489A (ja) 2016-03-03 2022-11-30 非ウイルス的遺伝子導入のための閉鎖型直鎖状二重鎖ｄｎａ

Country Status (18)

Country Link
US (3) US11066679B2 (cg-RX-API-DMAC7.html)
EP (2) EP3423110B1 (cg-RX-API-DMAC7.html)
JP (3) JP6994140B2 (cg-RX-API-DMAC7.html)
KR (1) KR102336362B1 (cg-RX-API-DMAC7.html)
CN (2) CN115287301A (cg-RX-API-DMAC7.html)
AU (2) AU2017228413B2 (cg-RX-API-DMAC7.html)
CA (1) CA3014683A1 (cg-RX-API-DMAC7.html)
DK (1) DK3423110T3 (cg-RX-API-DMAC7.html)
ES (1) ES2898337T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20211697T1 (cg-RX-API-DMAC7.html)
IL (2) IL261524B2 (cg-RX-API-DMAC7.html)
LT (1) LT3423110T (cg-RX-API-DMAC7.html)
MX (1) MX2018010633A (cg-RX-API-DMAC7.html)
PT (1) PT3423110T (cg-RX-API-DMAC7.html)
RU (1) RU2752882C2 (cg-RX-API-DMAC7.html)
SG (2) SG10201913688TA (cg-RX-API-DMAC7.html)
WO (1) WO2017152149A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201806544B (cg-RX-API-DMAC7.html)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201703148TA (en) 2014-11-05 2017-05-30 Voyager Therapeutics Inc Aadc polynucleotides for the treatment of parkinson's disease
DK3218386T3 (da) 2014-11-14 2021-06-07 Voyager Therapeutics Inc Modulatorisk polynukleotid
CA3193811A1 (en) 2014-11-14 2016-05-19 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
US11697825B2 (en) 2014-12-12 2023-07-11 Voyager Therapeutics, Inc. Compositions and methods for the production of scAAV
RU2752882C2 (ru) 2016-03-03 2021-08-11 Юниверсити Оф Массачусетс Линейная дуплексная днк с закрытым концом для невирусного переноса генов
AU2017267665C1 (en) 2016-05-18 2023-10-05 Voyager Therapeutics, Inc. Modulatory polynucleotides
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
KR102780287B1 (ko) 2017-08-09 2025-03-14 바이오버라티브 테라퓨틱스 인크. 핵산 분자 및 이의 용도
MX2020002501A (es) * 2017-09-08 2020-09-17 Generation Bio Co Formulaciones de nanoparticulas lipidas de vectores de adn libres de capsidos, no virales.
KR20200051011A (ko) * 2017-09-08 2020-05-12 제너레이션 바이오 컴퍼니 변형된 폐쇄-종결된 dna(cedna)
IL273448B2 (en) 2017-09-20 2025-05-01 Univ California A gene therapy strategy to restore electrical and cardiac function, and cardiac structure, in arrhythmogenic right ventricular cardiomyopathy
US12098385B2 (en) 2017-09-20 2024-09-24 The Regents Of The University Of California Gene therapy strategy to restore cardiac electrical and structural function in arrhythmogenic right ventricular cardiomyopathy
WO2019079362A1 (en) * 2017-10-16 2019-04-25 Massachusetts Institute Of Technology HOST-PATHOGENIC INTERACTION OF MYCOBACTERIUM TUBERCULOSIS
AU2018378672A1 (en) * 2017-12-06 2020-07-09 Generation Bio Co. Gene editing using a modified closed-ended dna (ceDNA)
US20210371877A1 (en) * 2017-12-18 2021-12-02 Spark Therapeutics, Inc. Adeno-associated virus (aav) vector lipid nanoparticle compositions and methods of use
SG11202005271TA (en) 2018-01-19 2020-07-29 Generation Bio Co Closed-ended dna vectors obtainable from cell-free synthesis and process for obtaining cedna vectors
CN111818942A (zh) * 2018-02-14 2020-10-23 世代生物公司 非病毒dna载体以及其用于产生抗体和融合蛋白的用途
CA3092059A1 (en) * 2018-02-22 2019-08-29 Generation Bio Co. Controlled expression of transgenes using close-ended dna (cedna) vectors
MA52116A (fr) * 2018-03-02 2021-01-06 Generation Bio Co Vecteurs d'adn à extrémité fermée (cedna) pour l'insertion de transgènes au niveau de havres génomiques sécuritaires (gsh) dans des génomes humains et murins
CA3092088A1 (en) * 2018-03-15 2019-09-19 Igtx, Llc Synthetic dna vectors and methods of use
WO2019191109A1 (en) * 2018-03-28 2019-10-03 The Board Of Trustees Of The Leland Stanford Junior University Microrna inhibitors and their use in treating epiretinal membranes
US12319929B2 (en) 2018-05-15 2025-06-03 Voyager Therapeutics, Inc. Compositions and methods for the treatment of Parkinson's disease
WO2019226650A1 (en) 2018-05-23 2019-11-28 Modernatx, Inc. Delivery of dna
WO2019237383A1 (zh) * 2018-06-16 2019-12-19 深圳市博奥康生物科技有限公司 用于人 tnfsf18 基因编辑的修饰载体、其制备方法及应用
WO2019237391A1 (zh) * 2018-06-16 2019-12-19 深圳市博奥康生物科技有限公司 CRISPR/Cas9 靶向敲除人 TXGP1 基因及其特异性 gRNA
EP3810782A2 (en) * 2018-06-22 2021-04-28 Asklepios Biopharmaceutical, Inc. Vectors for gene delivery that persist within cells
BR112021002017A2 (pt) 2018-08-09 2021-05-11 Bioverativ Therapeutics Inc. moléculas de ácido nucleico e usos das mesmas para terapia genética não viral
US20210310000A1 (en) * 2018-08-17 2021-10-07 City Of Hope Compounds of chemically modified oligonucleotides and methods of use thereof
CA3114621A1 (en) 2018-09-28 2020-04-02 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
BR112021007102A2 (pt) * 2018-11-09 2021-08-03 Generation Bio Co. dna com extremidade fechada modificada (cedna) que compreende repetições terminais invertidas modificadas simétricas
KR20210119416A (ko) * 2019-01-24 2021-10-05 제너레이션 바이오 컴퍼니 폐쇄-말단 dna (cedna), 및 유전자 또는 핵산 치료 관련 면역 반응을 감소시키는 방법에서의 이의 용도
WO2020168222A1 (en) * 2019-02-15 2020-08-20 Generation Bio Co. Modulation of rep protein activity in closed-ended dna (cedna) production
MA55223A (fr) * 2019-03-06 2022-01-12 Generation Bio Co Adn à extrémité fermée (cedna) et composés de modulation immunitaire
SG11202109426YA (en) * 2019-03-06 2021-09-29 Generation Bio Co Non-active lipid nanoparticles with non-viral, capsid free dna
EP3938515A4 (en) * 2019-03-13 2022-12-28 Generation Bio Co. NON-VIRAL DNA VECTORS AND THEIR USES FOR EXPRESSING PHENYLALANINE HYDROXYLASE (PAH) THERAPEUTIC AGENTS
KR20210151785A (ko) * 2019-03-13 2021-12-14 제너레이션 바이오 컴퍼니 비바이러스성 dna 벡터 및 fviii 치료제 발현을 위한 이의 용도
GB2617512B (en) * 2019-04-05 2023-12-27 Earli Inc Improved methods and compositions for synthetic biomarkers
CA3151464A1 (en) 2019-09-18 2021-03-25 Bruce C. SCHNEPP Synthetic dna vectors and methods of use
EP4110931A4 (en) 2020-02-25 2024-03-27 University of Massachusetts Inducible single aav system and uses thereof
AU2021241696A1 (en) 2020-03-27 2022-12-01 Generation Bio Co. Novel lipids and nanoparticle compositions thereof
US20210330759A1 (en) * 2020-04-22 2021-10-28 The Cleveland Clinic Foundation Methods and compositions for treating cytokine storm, ards, and acute lung injury using beta-glucocerebrosidase
AU2021285812A1 (en) 2020-06-01 2023-01-05 Modernatx, Inc. Phenylalanine hydroxylase variants and uses thereof
CA3189740A1 (en) 2020-07-27 2022-02-03 Anjarium Biosciences Ag Compositions of dna molecules, methods of making therefor, and methods of use thereof
CN116194152A (zh) 2020-08-23 2023-05-30 比奥维拉迪维治疗股份有限公司 用于改进封闭端DNA（ceDNA）的产生的经修饰的杆状病毒系统
AU2021342503A1 (en) * 2020-09-16 2023-04-06 Generation Bio Co. Non-viral DNA vectors and uses thereof for expressing FVIII therapeutics
KR20240005903A (ko) * 2021-05-07 2024-01-12 제너레이션 바이오 컴퍼니 백신 전달을 위한 비바이러스성 dna 벡터
CA3218126A1 (en) * 2021-05-07 2022-11-10 Matthew MANGANIELLO Lyophilized non-viral dna vector compositions and uses thereof
US20240263195A1 (en) 2021-05-11 2024-08-08 Modernatx, Inc. Non-viral delivery of dna for prolonged polypeptide expression in vivo
WO2023028004A1 (en) * 2021-08-23 2023-03-02 Avirmax, Inc. Compositions and methods for transgene expression
JP2024534123A (ja) 2021-08-23 2024-09-18 バイオベラティブ セラピューティクス インコーポレイテッド バキュロウイルス発現システム
CN114525282A (zh) * 2022-03-04 2022-05-24 西南大学 一种二价核酸适配体及其设计方法
IL322201A (en) * 2023-02-17 2025-09-01 Flagship Pioneering Innovations Vii Llc DNA structures containing modified uracil
WO2024197242A1 (en) 2023-03-23 2024-09-26 Carbon Biosciences, Inc. Protoparvovirus compositions comprising a protoparvovirus variant vp1 capsid polypeptide and related methods
WO2024249438A1 (en) * 2023-05-26 2024-12-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Copiparvovirus genetic vector platform
WO2025212926A1 (en) * 2024-04-05 2025-10-09 University Of Massachusetts Aav-mediated rhoa knockdown

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004508041A (ja) 2000-09-08 2004-03-18 メディジーン・アクチェンゲゼルシャフト 組換え型アデノ随伴ウイルス（ｒＡＡＶ）をパッケージングする親細胞、それらの生成方法、およびその使用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5252334A (en) 1989-09-08 1993-10-12 Cygnus Therapeutic Systems Solid matrix system for transdermal drug delivery
US5316908A (en) 1990-07-13 1994-05-31 Life Technologies, Inc. Size markers for electrophoretic analysis of DNA
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
AU689815B2 (en) * 1993-08-30 1998-04-09 Promega Corporation Nucleic acid purification compositions and methods
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5697899A (en) 1995-02-07 1997-12-16 Gensia Feedback controlled drug delivery system
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
US5656016A (en) 1996-03-18 1997-08-12 Abbott Laboratories Sonophoretic drug delivery system
US5797898A (en) 1996-07-02 1998-08-25 Massachusetts Institute Of Technology Microchip drug delivery devices
US5783208A (en) 1996-07-19 1998-07-21 Theratech, Inc. Transdermal drug delivery matrix for coadministering estradiol and another steroid
US7098320B1 (en) 1996-07-29 2006-08-29 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US5779708A (en) 1996-08-15 1998-07-14 Cyberdent, Inc. Intraosseous drug delivery device and method
IL128780A0 (en) 1996-09-06 2000-01-31 Univ Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing T7 polymerase
US6177403B1 (en) 1996-10-21 2001-01-23 The Trustees Of The University Of Pennsylvania Compositions, methods, and apparatus for delivery of a macromolecular assembly to an extravascular tissue of an animal
AU1750400A (en) 1998-12-04 2000-06-26 Mosaic Technologies, Inc. Method for the immobilization of oligonucleotides
US8241622B2 (en) * 2001-07-13 2012-08-14 University Of Iowa Research Foundation Adeno-associated virus vectors with intravector heterologous terminal palindromic sequences
KR101133799B1 (ko) 2006-08-18 2012-04-24 에프. 호프만-라 로슈 아게 폴리뉴클레오타이드의 생체내 전달을 위한 다가접합체
CA2927045A1 (en) 2006-10-03 2008-04-10 Muthiah Manoharan Lipid containing formulations
WO2009073809A2 (en) 2007-12-04 2009-06-11 Alnylam Pharmaceuticals, Inc. Carbohydrate conjugates as delivery agents for oligonucleotides
US8507455B2 (en) 2007-12-04 2013-08-13 Alnylam Pharmaceuticals, Inc. Folate conjugates
LT2440183T (lt) 2009-06-10 2018-08-10 Arbutus Biopharma Corporation Patobulinta lipido kompozicija
WO2012068187A1 (en) 2010-11-19 2012-05-24 Merck Sharp & Dohme Corp. Poly(amide) polymers for the delivery of oligonucleotides
EP2500434A1 (en) * 2011-03-12 2012-09-19 Association Institut de Myologie Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery
RU2752882C2 (ru) 2016-03-03 2021-08-11 Юниверсити Оф Массачусетс Линейная дуплексная днк с закрытым концом для невирусного переноса генов

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004508041A (ja) 2000-09-08 2004-03-18 メディジーン・アクチェンゲゼルシャフト 組換え型アデノ随伴ウイルス（ｒＡＡＶ）をパッケージングする親細胞、それらの生成方法、およびその使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Virology Journal，2005年，vol.2, no.43，p.1-17

Also Published As

Publication number Publication date
EP3423110A1 (en) 2019-01-09
IL261524B2 (en) 2023-10-01
CN109195636A (zh) 2019-01-11
IL302398B2 (en) 2025-06-01
CN115287301A (zh) 2022-11-04
JP7193096B2 (ja) 2022-12-20
US11066679B2 (en) 2021-07-20
US20250290094A1 (en) 2025-09-18
IL302398A (en) 2023-06-01
MX2018010633A (es) 2019-06-13
RU2018134295A (ru) 2020-04-06
EP3423110A4 (en) 2019-09-11
DK3423110T3 (da) 2021-11-15
NZ744961A (en) 2025-06-27
JP2019506889A (ja) 2019-03-14
US12252703B2 (en) 2025-03-18
WO2017152149A1 (en) 2017-09-08
ZA201806544B (en) 2022-07-27
US20220195456A9 (en) 2022-06-23
CA3014683A1 (en) 2017-09-08
LT3423110T (lt) 2021-12-27
SG10201913688TA (en) 2020-03-30
AU2017228413A1 (en) 2018-08-23
RU2018134295A3 (cg-RX-API-DMAC7.html) 2020-06-29
AU2017228413B2 (en) 2025-01-23
IL261524B1 (en) 2023-06-01
EP3957331A1 (en) 2022-02-23
KR102336362B1 (ko) 2021-12-08
ES2898337T3 (es) 2022-03-07
HRP20211697T1 (hr) 2022-02-04
PT3423110T (pt) 2021-11-09
JP2023024489A (ja) 2023-02-16
KR20180117171A (ko) 2018-10-26
SG11201806663TA (en) 2018-09-27
EP3423110B1 (en) 2021-08-11
IL261524A (en) 2018-10-31
RU2752882C2 (ru) 2021-08-11
US20190032083A1 (en) 2019-01-31
JP2022025123A (ja) 2022-02-09
AU2025202724A1 (en) 2025-05-08
CN109195636B (zh) 2022-07-05
IL302398B1 (en) 2025-02-01
US20210355507A1 (en) 2021-11-18

Similar Documents

Publication Publication Date Title
JP6994140B2 (ja) 非ウイルス的遺伝子導入のための閉鎖型直鎖状二重鎖ｄｎａ
AU2020342668B2 (en) Lipid nanoparticle compositions comprising closed-ended DNA and cleavable lipids and methods of use thereof
JP7237843B2 (ja) 修飾されたａａｖキャプシドタンパク質およびその使用
JP2023100680A (ja) 筋萎縮性側索硬化症（ａｌｓ）治療組成物および方法
WO2023284879A1 (en) Modified aav capsid for gene therapy and methods thereof
CN111108198A (zh) 治疗亨廷顿病的组合物和方法
CA3075168A1 (en) Modified closed-ended dna (cedna)
US20220127625A1 (en) Modulation of rep protein activity in closed-ended dna (cedna) production
CA3092059A1 (en) Controlled expression of transgenes using close-ended dna (cedna) vectors
CN111876432B (zh) 一组肝靶向新型腺相关病毒的获得及其应用
JP2025518145A (ja) 修飾されたアデノ随伴ウイルスカプシドタンパク質及びその方法
US20240307557A1 (en) Therapeutic gene silencing with crispr-cas13
HK40069282A (en) Closed-ended linear duplex dna for non-viral gene transfer
US20260001917A1 (en) Modified adeno-associated virus capsid proteins and methods thereof
HK40002860B (en) Closed-ended linear duplex dna for non-viral gene transfer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200302

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200302

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210308

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210607

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210702

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210830

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210929

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20211025

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20211025

R150 Certificate of patent or registration of utility model

Ref document number: 6994140

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250